瑞科生物：REC603与BE公司达成产品授权合作

Core Viewpoint - The company has signed a product licensing cooperation agreement with Indian BE Company for the restructuring of the nine-valent HPV vaccine REC603, granting exclusive rights for development, production, and commercialization in India and in tender markets led by UNICEF and PAHO [1] Group 1 - The company has received an upfront payment for the collaboration [1] - The company will receive milestone payments based on the progress of the collaboration [1] - The company will also earn royalties based on annual net sales [1]